RSV in Adults

Reviewed by Ann Dietrich, MD, FAAP, FACEP 

Key Takeaways

Although respiratory syncytial virus (RSV) is often framed as a pediatric pathogen, it is also a clinically important cause of respiratory morbidity in adults, particularly in those aged 75 years and older and in adults aged 50 to 74 years with risk factors for severe disease. In adults, RSV typically presents as an acute respiratory illness with cough, congestion, rhinorrhea, and fatigue, but it can progress to lower respiratory tract disease, including pneumonia, and can precipitate exacerbations of chronic obstructive pulmonary disease (COPD), asthma, and heart failure. Diagnostic overlap with influenza and COVID-19 is substantial, making molecular testing useful when results will change management.  

Treatment in most immunocompetent adults remains supportive, as there is no routinely recommended antiviral therapy for typical adult RSV infection. Prevention is therefore central, and current Centers for Disease Control and Prevention (CDC) RSV guidance recommends a single dose of vaccine for all adults age 75 years and older and for adults ages 50 to 74 years who are at increased risk of severe RSV illness.  

Introduction

Respiratory syncytial virus is increasingly recognized as a significant pathogen in adult medicine, not only in geriatric and pulmonary practice but also in primary care, urgent care, hospital medicine, and long-term care settings. While many adult infections are mild and self-limited, RSV can cause substantial disease burden in older adults, frail individuals, nursing home residents, and adults with chronic cardiopulmonary disease, renal disease, diabetes with end-organ involvement, severe obesity, neurologic disease affecting airway clearance, or moderate to severe immunocompromise.  

The CDC now recommends a single dose of RSV vaccine for all adults ages 75 years and older and for adults ages 50 to 74 years who are at increased risk, reflecting the growing recognition that RSV is not merely a childhood illness but a major adult respiratory pathogen.  

Why RSV matters in adults

In adults, RSV occupies an important place in the differential diagnosis of seasonal respiratory illness because the clinical burden extends beyond uncomplicated upper respiratory tract infection. RSV can lead to lower respiratory tract disease, hospitalization, and decompensation of chronic illnesses. The CDC notes that RSV can be dangerous for older adults, especially those who are elderly or frail, have certain medical conditions, or live in nursing homes. The CDC also estimates that each year RSV leads to a substantial number of hospitalizations among U.S. adults age 50 years and older.  

The clinical consequences are especially relevant in patients with underlying lung and heart disease. RSV may trigger COPD and asthma exacerbations, worsen baseline respiratory reserve, and contribute to heart failure destabilization through increased cardiopulmonary stress. For inpatient and post-acute care clinicians, RSV should therefore be viewed as a meaningful driver of winter respiratory admissions rather than a minor viral syndrome.  

Clinical presentation in adults

Adult RSV infection most commonly presents with cold-like symptoms, including rhinorrhea, nasal congestion, cough, fatigue, and sometimes fever. Symptom onset generally occurs four to six days after infection. Although many adults recover within one to two weeks, the course can be more severe in high-risk populations.  

In contrast with influenza, which often begins abruptly, RSV symptoms may evolve more progressively. In older adults, clinicians should be alert for transition from upper respiratory symptoms to dyspnea, wheezing, hypoxemia, or radiographic evidence of lower respiratory tract disease. Monitoring  for escalation should be elevated  in frail adults and in those with reduced cardiopulmonary reserve.  

Which adults are at highest risk?

Current CDC guidance identifies several groups at increased risk for severe RSV illness. These include all adults age 75 years and older, as well as adults ages 50 to 74 years with chronic cardiovascular disease, chronic lung disease, end-stage renal disease or dialysis dependence, diabetes complicated by chronic kidney disease or other end-organ damage, neurologic or neuromuscular disease that impairs airway clearance, chronic liver disease, chronic hematologic disease, severe obesity, moderate or severe immune compromise, or nursing home residence. The CDC also allows clinician judgment for frailty and other circumstances that increase the risk associated with viral respiratory infection.  

This risk-based framework is clinically useful beyond vaccination decisions. It also helps guide testing decisions, anticipatory counseling, and disposition. A 52-year-old patient with insulin-treated diabetes and chronic kidney disease should not be approached in the same manner as a healthy 52-year-old with self-limited cough and congestion.  

Diagnostic approach in adults

Because RSV symptoms overlap with influenza, COVID-19, and other viral respiratory infections, diagnosis based on symptoms alone is unreliable. Laboratory confirmation is most useful when results will change treatment decisions, infection prevention measures, patient cohorting, or overall management strategy.  

The CDC identifies nucleic acid amplification tests (NAATs), including polymerase chain reaction (PCR)-based assays, as highly sensitive tests for RSV detection. Antigen tests can provide quicker results but are generally less sensitive than NAATs. This distinction matters in adults, in whom lower viral shedding may reduce the diagnostic yield of less sensitive assays. In many clinical settings, multiplex molecular respiratory panels can be particularly helpful because they assess for RSV, influenza, and SARS-CoV-2 simultaneously during periods of cocirculation.  

For most otherwise healthy outpatients with mild disease, RSV-specific confirmation may not alter management. However, in high-risk adults, hospitalized patients, nursing home residents, and those who may qualify for influenza or COVID-directed therapy, testing can be clinically consequential.  

Treatment of RSV in adults

Treatment for most immunocompetent adults with RSV is supportive. The CDC states that most RSV symptoms can be managed with over-the-counter medications and supportive care. In practice, adult management centers on hydration, antipyretics or analgesics when appropriate, rest, and monitoring for progression to lower respiratory tract disease.  

There is no routinely recommended antiviral therapy for typical RSV infection in otherwise immunocompetent adults. Accordingly, treatment decisions should focus on severity assessment, oxygenation, symptom burden, hydration status, and the presence of exacerbated underlying disease. If an adult with RSV develops COPD exacerbation, asthma worsening, or heart failure decompensation, management should address both the viral trigger and the organ-specific complication.  

In the outpatient setting, clinicians should counsel patients to seek reassessment for increasing dyspnea, chest pain, inability to maintain oral intake, altered mental status, persistent hypoxemia if being monitored at home, or worsening symptoms after several days of illness.  

In the inpatient setting, supportive care may include supplemental oxygen, bronchodilator therapy when clinically indicated for reactive airway disease, intravenous fluids when needed, and treatment of secondary complications or disease exacerbations. These supportive measures are based on standard adult respiratory care. The CDC’s RSV patient guidance emphasizes supportive management rather than virus-specific outpatient treatment.  

Infection control and transmission in adults

RSV is contagious and spreads through respiratory droplets, direct contact, and contaminated surfaces. Adults can transmit infection even when symptoms are mild, which is especially relevant in households with infants, among caregivers, and in congregate settings such as skilled nursing facilities.  

For clinicians caring for older adults and long-term care populations, RSV should remain part of seasonal outbreak recognition. Early identification of clusters, symptomatic testing when appropriate, and standard respiratory infection control practices can help reduce transmission to patients at elevated risk for severe disease.  

Prevention in adults

Prevention has become the central adult RSV strategy. The CDC currently recommends a single dose of RSV vaccine for all adults age 75 years and older and for adults ages 50 to 74 years who are at increased risk of severe RSV illness. There are three Food and Drug Administration-licensed adult RSV vaccines, and the CDC does not state a preference for one specific product over another. The CDC also notes that RSV vaccine is not currently an annual vaccine.  

For eligible adults in the continental United States, vaccination in late summer to early fall is generally expected to provide the greatest seasonal benefit, although eligible patients may receive the vaccine at any time of year. In clinical practice, this is particularly important for adults with chronic lung disease, advanced age, frailty, or nursing home residence, who may be at disproportionate risk for hospitalization from RSV.

FAQ

How serious is RSV in adults?

RSV in adults is often mild, but it can be serious in older adults, frail individuals, nursing home residents, and adults with chronic heart or lung disease, immunocompromise, or other major comorbidities. Severe disease may include pneumonia, hospitalization, and exacerbation of chronic cardiopulmonary conditions.  

How is RSV treated in adults?

Most adults are treated with supportive care rather than a virus-specific medication. Management generally includes hydration, symptom relief, and monitoring for lower respiratory tract involvement or exacerbation of underlying disease.  

Should adults be tested for RSV?

Adults should be tested when the result will affect management, infection control, or diagnostic clarity, especially when influenza and COVID-19 are also circulating or when the patient is high-risk. NAAT/PCR testing is generally more sensitive than antigen testing.  

Which adults should get the RSV vaccine?

The CDC recommends one dose for all adults age 75 years and older and for adults ages 50 to 74 years who are at increased risk of severe RSV illness.  

Is RSV in adults different from RSV in infants?

Yes. Adults more often present with upper respiratory symptoms and may have milder disease overall, whereas infants are more likely to develop bronchiolitis and feeding-related complications. However, older and medically complex adults can also develop severe lower respiratory disease.